Drug Profile
Research programme: Duchenne muscular dystrophy gene therapy - uniQure
Alternative Names: AMT-080Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amsterdam Molecular Therapeutics
- Developer uniQure
- Class Gene therapies
- Mechanism of Action Dystrophin stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Netherlands (Parenteral)
- 12 Mar 2012 Preclinical trials in Duchenne muscular dystrophy in Netherlands (Parenteral)
- 25 Oct 2011 Suspended - Preclinical for Duchenne muscular dystrophy in Netherlands (Parenteral)